Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
Bladder cancer is not a rare disease. It is one of the 10 most common cancers in the UK and the 5th most common cancer in the European Union.
Read Full NewsThe pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.
Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.
Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO
1.
Healthy weight loss could lower your odds for cancer
2.
An inoperable locally advanced NSCLC trial dubbed "Practice Changing".
3.
Study: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy
4.
Specialist Referrals Are Critical for Functional High-Risk Multiple Myeloma
5.
In cases of metastatic or recurrent head and neck cancer, gene-guided immunotherapy falls short.
1.
Unlocking the Mystery of Methaemoglobinaemia: A New Hope for Treatment
2.
Clinical Analysis of Prostate Cancer
3.
What You Need To Know About Secondary Polycythemia: Treatment & Symptoms
4.
AI on the Front Lines: Revolutionizing Breast Cancer Detection with Artificial Intelligence
5.
Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
2.
Navigating the Complexities of Ph Negative ALL - Part II
3.
Updates on the First Line Management of ALK+ NSCLC
4.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge